Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year High – Here’s Why

Sionna Therapeutics, Inc. (NASDAQ:SION)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $51.73 and last traded at $51.5550, with a volume of 318131 shares. The stock had previously closed at $49.26.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. BTIG Research restated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Freedom Capital lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Wall Street Zen lowered Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wedbush started coverage on Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target on the stock. Finally, Citizens Jmp restated a “market outperform” rating and set a $63.00 price objective on shares of Sionna Therapeutics in a report on Tuesday, May 26th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Trading Up 1.4%

The firm has a market capitalization of $2.25 billion, a P/E ratio of -25.88 and a beta of 1.32. The stock has a 50-day simple moving average of $41.83 and a two-hundred day simple moving average of $40.14.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, research analysts expect that Sionna Therapeutics, Inc. will post -2.57 EPS for the current year.

Insiders Place Their Bets

In related news, Director Peter A. Thompson sold 85,918 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director directly owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. The trade was a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 989,630 shares of company stock valued at $44,987,483 over the last 90 days. 5.10% of the stock is currently owned by company insiders.

Institutional Trading of Sionna Therapeutics

Large investors have recently bought and sold shares of the stock. Viking Global Investors LP increased its stake in Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Sionna Therapeutics by 30.1% during the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after buying an additional 335,942 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sionna Therapeutics by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after acquiring an additional 41,797 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Sionna Therapeutics by 30.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock valued at $34,203,000 after acquiring an additional 193,613 shares during the period. Finally, State Street Corp raised its stake in Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after acquiring an additional 453,196 shares during the last quarter.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.